A growing number of dermatology clinics in South Korea are prioritizing aesthetic treatments such as botulinum toxin and filler injections over medical dermatology, driven by the country's fee-for-service reimbursement system. For overseas buyers of aesthetic devices and injectables, this structural shift signals sustained demand for non-reimbursed aesthetic products and highlights the importance of targeting clinics that focus on cosmetic procedures.
Market signal
South Korea's dermatology market is experiencing a pronounced shift toward aesthetic procedures. According to the Ministry of Health and Welfare, the number of foreign patients visiting Korea reached 2.01 million in 2025, with dermatology accounting for 1.313 million patients (62.9%), up 86.2% year-on-year. Plastic surgery followed with 233,000 patients (11.2%), up 64.3%. This surge is fueling demand for botulinum toxin, fillers, and laser devices.
Reimbursement structure driving clinic behavior
Under Korea's fee-for-service system, reimbursed medical dermatology treatments—such as for atopic dermatitis, eczema, and burns—are priced by the government, limiting clinic revenue regardless of time or effort. In contrast, aesthetic procedures like botox, fillers, and lasers are mostly non-reimbursed, allowing clinics to set prices freely. This economic incentive is pushing many clinics to focus on cosmetic services.
Specialist vs. general practitioner landscape
Among approximately 15,000 clinics offering dermatology services in Korea, only about 1,516 are run by board-certified dermatologists. Any licensed physician can legally practice dermatology and perform aesthetic procedures, making it difficult for patients to distinguish between specialist-led clinics and those operated by general practitioners or other specialists. This regulatory environment further encourages the shift toward higher-margin aesthetic services.
What buyers should watch
For overseas distributors and clinic buyers, the Korean market's structural tilt toward aesthetics means sustained demand for non-reimbursed injectables (botulinum toxin, fillers) and energy-based devices. Key suppliers include Hugel (botulinum toxin and HA fillers), Medytox (toxin and filler lines), and Daewoong Pharmaceutical (Nabota toxin). These companies are expanding international approvals and hospital-channel sales, making them strategic partners for importers targeting the aesthetic segment.
Regulatory and channel signals
The trend is not driven by individual ethics but by the economic structure of Korea's healthcare market, as noted by Professor Lee Moon-jae of Yonsei University. Policymakers are under pressure to adjust reimbursement rates for medical dermatology to prevent treatment gaps. For now, the imbalance favors aesthetic-focused clinics, reinforcing the channel for premium aesthetic products. Importers should monitor reimbursement policy changes that could alter clinic behavior, but the near-term outlook remains strongly pro-aesthetic.
Source: Read the original report | Published: June 14, 2026